Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (61)

Search Parameters:
Keywords = powder aerosol deposition

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
26 pages, 6909 KiB  
Article
Development of Voriconazole Proliposome Based Dry Powder for Inhalation: A Design of Experiment Approach
by Sanjeevani Deshkar, Alisha Vas, Roshani Pagar, Prabhanjan Giram, Asha Thomas and Vaishali Undale
Pharmaceutics 2025, 17(5), 622; https://doi.org/10.3390/pharmaceutics17050622 - 8 May 2025
Viewed by 700
Abstract
The present investigation aimed to formulate and optimize sustained release proliposome dry powder for inhalation of Voriconazole (VZ) and its in vitro and in vivo evaluation. The proliposome-based dry powder for inhalation was formulated by spray drying technique using Phospholipon 90H and cholesterol [...] Read more.
The present investigation aimed to formulate and optimize sustained release proliposome dry powder for inhalation of Voriconazole (VZ) and its in vitro and in vivo evaluation. The proliposome-based dry powder for inhalation was formulated by spray drying technique using Phospholipon 90H and cholesterol in the lipid phase, mannitol as a carrier, and L-leucine as a dispersing agent. A face-centered central composite design was used to study the influence of factors on responses, vesicle size, VZ entrapment efficiency, and drug release. The optimized formulation was further characterized by FTIR, FESEM, DSC, XRD, and evaluated for in vitro drug release, in vitro aerosol deposition, and in vivo lung retention study in Wistar rats. For the optimized batch F-5 proliposome formulation, vesicle size was observed as 191.7 ± 0.049 nm with PDI 0.328 ± 0.009, entrapment efficiency as 72.94 ± 0.56%, and cumulative drug release after 8 h of dissolution was 82.0 ± 0.14%. The median mass aerodynamic diameter (MMAD) generated by optimized formulation F5 was significantly lower (3.85 ± 0.15 µm, p < 0.0001) as compared to spray-dried voriconazole (SD-VZ) (8.35 ± 0.23 µm). In vivo studies demonstrated a profound enhancement in lung retention (3.8-fold) compared to SD-VZ and oral VZ dispersion. Conclusively, proliposome formulation of voriconazole is a plausible and convincing approach for pulmonary fungal infections, considering its sustained release behaviour and prolonged lung retention. Full article
Show Figures

Figure 1

10 pages, 4617 KiB  
Article
Aerosol Deposited Polycrystalline PbZr0.53Ti0.47O3 Thick Films with a Large Transverse Piezoelectric Coefficient
by Long Teng, Juan Yang, Yongguang Xiao, Hongbo Cheng, Shibo Gong, Gao Luo, Jinlin Yang, Wenjia Zhang, Zhenwei Shen and Jun Ouyang
Crystals 2025, 15(2), 159; https://doi.org/10.3390/cryst15020159 - 5 Feb 2025
Viewed by 2856
Abstract
The aerosol deposition (AD) method utilizes high kinetic-energy submicron powders to impact and form a film on a substrate. It is a highly efficient deposition method, capable of producing films or coatings with a strong interfacial bonding and a dense nano-grain structure without [...] Read more.
The aerosol deposition (AD) method utilizes high kinetic-energy submicron powders to impact and form a film on a substrate. It is a highly efficient deposition method, capable of producing films or coatings with a strong interfacial bonding and a dense nano-grain structure without thermal assistance. In this work, PbZr0.53Ti0.47O3 (PZT53/47) films (~1.2 μm thick) were deposited on Pt/Ti/Si(100) substrates via the AD method. After a conventional annealing process (700 °C for 1 h), these PZT53/47 films displayed a dense, crack-free, nano-grained morphology, corresponding to an optimal electrical performance. A large maximum polarization (Pmax = 70 μC/cm2) and a small coercive field (Ec = 104 kV/cm) were achieved under the maximum applicable electric field of 1.6 MV/cm. The PZT53/47 films also exhibited a large small-field dielectric constant of ~984, a high tunability of 72%, and a low leakage current of ~3.1 × 10−5 A/cm2 @ 40 V. Moreover, the transverse piezoelectric coefficient (e31.f) of these AD-processed films was as high as −4.6 C/m2, comparable to those of sputter-deposited PZT53/47 films. These high-quality PZT53/47 thick films have broad applications in piezoelectric micro-electromechanical systems. Full article
Show Figures

Figure 1

34 pages, 1732 KiB  
Review
Dry Powder Inhalers for Delivery of Synthetic Biomolecules
by Hossein Omidian, Ali Nokhodchi and Niloofar Babanejad
Pharmaceuticals 2025, 18(2), 175; https://doi.org/10.3390/ph18020175 - 27 Jan 2025
Cited by 2 | Viewed by 2498
Abstract
This manuscript provides a comprehensive review of advancements in dry powder inhaler (DPI) technology for pulmonary and systemic drug delivery, focusing on proteins, peptides, nucleic acids, and small molecules. Innovations in spray-drying (SD), spray freeze-drying (SFD), and nanocarrier engineering have led to enhanced [...] Read more.
This manuscript provides a comprehensive review of advancements in dry powder inhaler (DPI) technology for pulmonary and systemic drug delivery, focusing on proteins, peptides, nucleic acids, and small molecules. Innovations in spray-drying (SD), spray freeze-drying (SFD), and nanocarrier engineering have led to enhanced stability, bioactivity, and aerosol performance. Studies reveal the critical role of excipients, particle morphology, and device design in optimizing deposition and therapeutic efficacy. Applications include asthma, cystic fibrosis, tuberculosis (TB), and lung cancer, with emerging platforms such as ternary formulations and siRNA-loaded systems demonstrating significant clinical potential. Challenges such as stability, scalability, and patient adherence are addressed through novel strategies, including Quality by Design (QbD) approaches and advanced imaging tools. This work outlines pathways for future innovation in pulmonary drug delivery. Full article
(This article belongs to the Section Pharmaceutical Technology)
Show Figures

Figure 1

19 pages, 7317 KiB  
Article
Development and Characterization of Spray-Dried Combined Levofloxacin–Ambroxol Dry Powder Inhaler Formulation
by Ruwani K. Suraweera, Kirsten M. Spann, Emad L. Izake, Timothy J. Wells, Xiaodong Wang and Nazrul Islam
Pharmaceutics 2024, 16(12), 1506; https://doi.org/10.3390/pharmaceutics16121506 - 22 Nov 2024
Cited by 2 | Viewed by 1461
Abstract
Background: This study explores the development and characterization of spray-dried composite microparticles consisting of levofloxacin (LVX, a broad-spectrum antibiotic), and ambroxol (AMB, a mucolytic agent that has antibacterial and antibiofilm properties), for the intended application of the drug against lower respiratory tract infections [...] Read more.
Background: This study explores the development and characterization of spray-dried composite microparticles consisting of levofloxacin (LVX, a broad-spectrum antibiotic), and ambroxol (AMB, a mucolytic agent that has antibacterial and antibiofilm properties), for the intended application of the drug against lower respiratory tract infections (LRTIs). Methods: A range of LVX to AMB mass ratios (1:1, 1:0.5, and 1:0.25) were prepared, with and without the use of the dispersibility enhancer leucine (LEU), and spray-dried following pre-optimized parameters to achieve the required particle size (1–5 µm) and flow properties. The formulations were characterized by attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy, scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), and a thermogravimetric analysis (TGA). The in vitro aerosolization performance of the new formulation was evaluated with a twin-stage impinger (TSI) at a flow rate of 60 ± 5 L/min. Using a validated RP-HPLC method, LVX and AMB were quantitatively determined. Results: The combined spray-dried LVX, AMB, and LEU particles were spherically shaped with sizes ranging from 1.9 to 2.9 µm, thus complying with the size requirements for effective deep lung deposition. The dispersibility enhancer leucine produced a high yield and enhanced the flow properties and aerosolization characteristics of the spray-dried formulations. The LVX to AMB mass ratios showed a remarkable impact on the aerosolization properties, with the LVX to AMB 1:1 mass ratio demonstrating the best flow and FPFs for both drugs. There must be a balanced ratio of these components for spray drying the composite particles to obtain composite particles of the required size and with the appropriate flow property. The addition of 5% of LEU significantly (p < 0.005) improved the FPF of all the formulations, probably by enhancing the surface hydrophobicity of the composite particles. Conclusions: The spray-dried combined antibiotics formulation has a strong potential for efficient lung delivery intended for the management of LRTIs. Full article
(This article belongs to the Special Issue Development of Spray-Dried Powders for Pulmonary Drug Delivery)
Show Figures

Figure 1

14 pages, 5518 KiB  
Article
In Vitro Analysis of Aerodynamic Properties and Co-Deposition of a Fixed-Dose Combination of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate
by Kittipong Maneechotesuwan, Somchai Sawatdee and Teerapol Srichana
Pharmaceutics 2024, 16(10), 1334; https://doi.org/10.3390/pharmaceutics16101334 - 18 Oct 2024
Viewed by 1776
Abstract
Background/Objectives: Effective airway delivery of a fixed-dose combination of triple-aerosolized inhaled corticosteroid (ICS)/long-acting beta agonist (LABA)/long-acting muscarinic antagonist (LAMA) is likely to positively affect therapeutic responses predicted in patients with asthma and chronic obstructive pulmonary disease. This study aimed to conduct in vitro [...] Read more.
Background/Objectives: Effective airway delivery of a fixed-dose combination of triple-aerosolized inhaled corticosteroid (ICS)/long-acting beta agonist (LABA)/long-acting muscarinic antagonist (LAMA) is likely to positively affect therapeutic responses predicted in patients with asthma and chronic obstructive pulmonary disease. This study aimed to conduct in vitro fluticasone furoate, vilanterol trifenatate, and umeclidinium bromide depositions in a Next Generation Impactor. The aerodynamic properties of these inhaled medications influence the spatial distribution and drug abundance, particularly in the smaller airways, to reverse or alleviate disease pathology. Methods: The Next Generation Impactor was used to demonstrate the aerodynamic particle size distributions of fluticasone furoate, vilanterol trifenatate, and umeclidinium bromide delivered from a dry powder inhaler at different flow rates across all stages of the impactors. This in vitro study analyzed the distribution pattern of individual drug components to simulate mono-component deposition and co-deposition in the official model in the United States Pharmacopeia. An Andersen cascade impactor together with scanning electron microscope–energy-dispersive X-ray was employed to observe the drug deposition on each stage of the impactor. Results: We found that the distribution pattern of each component at the same cascade level was comparable, and the aerosol particles of the three drugs reached the in vitro representation of the lower airway compartment. The specified flow rates generated the desired fine particle fraction, fine particle dose, and mass median aerodynamic diameter. Our results also demonstrated visualized deposition patterns of the delivered drugs from different stages of the cascade impactor that may predict deposition as it occurs in vivo. Conclusions: Spatial distribution and abundance of ICS/LABA/LAMA in the same cascade levels were closely comparable, and the aerosol particles were able to reach the small aerosol-sized cascades at the lower levels to some extent. Full article
Show Figures

Figure 1

13 pages, 4392 KiB  
Article
Aerosol-Deposited 8YSZ Coating for Thermal Shielding of 3YSZ/CNT Composites
by Maria Wiśniewska, Grzegorz Kubicki, Mateusz Marczewski, Volf Leshchynsky, Luca Celotti, Mirosław Szybowicz and Dariusz Garbiec
Coatings 2024, 14(9), 1186; https://doi.org/10.3390/coatings14091186 - 13 Sep 2024
Cited by 1 | Viewed by 2293
Abstract
High-temperature conditions are harmful for carbon nanotube-based (CNT-based) composites, as CNTs are susceptible to oxidation. On the other hand, adding CNTs to ceramics with low electrical conductivity, such as 3YSZ, is beneficial because it allows the production of complex-shaped samples with spark plasma [...] Read more.
High-temperature conditions are harmful for carbon nanotube-based (CNT-based) composites, as CNTs are susceptible to oxidation. On the other hand, adding CNTs to ceramics with low electrical conductivity, such as 3YSZ, is beneficial because it allows the production of complex-shaped samples with spark plasma sintering (SPS). A shielding coating system may be applied to prevent CNT oxidation. In this work, the 8YSZ (yttria-stabilized zirconia) thermal shielding coating system was deposited by aerosol deposition (AD) to improve the composite’s resistance to CNT degradation without the use of bond-coat sublayers. Additionally, the influence of the annealing process on the mechanical properties and microstructure of the composite was evaluated by nanoindentation, scratch tests, scanning electron microscopy (SEM), X-ray diffraction (XRD), flame tests, and light microscopy (LM). Annealing at 1200 °C was the optimal temperature for heat treatment, improving the coating’s mechanical strength (the first critical load increased from 0.84 N to 3.69 N) and promoting diffusion bonding between the compacted powder particles and the substrate. The deposited coating of 8YSZ increased the composite’s thermal resistance by reducing the substrate’s heating rate and preventing the oxidation of CNTs. Full article
Show Figures

Figure 1

20 pages, 5753 KiB  
Article
A Critical Analysis of the CFD-DEM Simulation of Pharmaceutical Aerosols Deposition in Upper Intra-Thoracic Airways: Considerations on Aerosol Transport and Deposition
by Georgi H. Spasov, Riccardo Rossi, Andrea Vanossi, Ciro Cottini and Andrea Benassi
Pharmaceutics 2024, 16(9), 1119; https://doi.org/10.3390/pharmaceutics16091119 - 24 Aug 2024
Cited by 2 | Viewed by 1768
Abstract
The reliability and accuracy of numerical models and computer simulations to study aerosol deposition in the human respiratory system is investigated for a patient-specific tracheobronchial tree geometry. A computational fluid dynamics (CFD) model coupled with discrete elements methods (DEM) is used to predict [...] Read more.
The reliability and accuracy of numerical models and computer simulations to study aerosol deposition in the human respiratory system is investigated for a patient-specific tracheobronchial tree geometry. A computational fluid dynamics (CFD) model coupled with discrete elements methods (DEM) is used to predict the transport and deposition of the aerosol. The results are compared to experimental and numerical data available in the literature to study and quantify the impact of the modeling parameters and numerical assumptions. Even if the total deposition compares very well with the reference data, it is clear from the present work how local deposition results can depend significantly upon spatial discretization and boundary conditions adopted to represent the respiratory act. The modeling of turbulent fluctuations in the airflow is also found to impact the local deposition and, to a minor extent, the flow characteristics at the inlet of the computational domain. Using the CFD-DEM model, it was also possible to calculate the airflow and particles splitting at bifurcations, which were found to depart from the assumption of being equally distributed among branches adopted by some of the simplified deposition models. The results thus suggest the need for further studies towards improving the quantitative prediction of aerosol transport and deposition in the human airways. Full article
Show Figures

Figure 1

9 pages, 3880 KiB  
Article
Effect of Interlayer on Flatness and Adhesion of Aerosol-Deposited Yttrium Oxide Coating
by Ki-Seong Lim, Tae-Soo Jang, Jae-hyeon Jeong, Sung-Hwan Hong and Joo Jin
Materials 2024, 17(14), 3533; https://doi.org/10.3390/ma17143533 - 17 Jul 2024
Cited by 1 | Viewed by 1211
Abstract
In this study, Y2O3 coating is used as an interlayer between Al2O3 substrate and a ceramic coating; this is in order to minimize the morphological distortion produced by a single deposition of the ceramic coating on the [...] Read more.
In this study, Y2O3 coating is used as an interlayer between Al2O3 substrate and a ceramic coating; this is in order to minimize the morphological distortion produced by a single deposition of the ceramic coating on the Al2O3 substrate, which is performed using the aerosol method. The interlayer coating, which comprises the Y2O3 phase, is deposited on the Al2O3 substrate using an e-beam evaporator. The crystal structure of the powder that was used to process the coating is identified as cubic Y2O3. In contrast, the crystal structure of the top-coating layer and interlayer indicates the presence of two kinds of Y2O3 phases, which possess cubic and monoclinic structures. The single Y2O3 coating without an interlayer exhibits microcracks around the interface between the coating and the substrate, which can be attributed to the stress that occurs during aerosol deposition. In contrast, no cracks are found in the aerosol-deposited Y2O3 coating and interlayer, which show a desirable microstructure. The single Y2O3 coating and the Y2O3 coating with an interlayer exhibit similar hardness and elastic modulus values. Nevertheless, the Y2O3 coating with an interlayer exhibits a higher level of adhesion than the single Y2O3 coating, with a value of 14.8 N compared to 10.2 N. Full article
(This article belongs to the Special Issue Characterization, Properties, and Applications of New Metallic Alloys)
Show Figures

Figure 1

18 pages, 6600 KiB  
Article
Design of Experiment (DoE) Approach for Developing Inhalable PLGA Microparticles Loaded with Clofazimine for Tuberculosis Treatment
by Druva Sarika Rongala, Suyash M. Patil and Nitesh K. Kunda
Pharmaceuticals 2024, 17(6), 754; https://doi.org/10.3390/ph17060754 - 7 Jun 2024
Cited by 3 | Viewed by 2031
Abstract
Tuberculosis (TB) is an airborne bacterial infection caused by Mycobacterium tuberculosis (M. tb), resulting in approximately 1.3 million deaths in 2022 worldwide. Oral therapy with anti-TB drugs often fails to achieve therapeutic concentrations at the primary infection site (lungs). In this [...] Read more.
Tuberculosis (TB) is an airborne bacterial infection caused by Mycobacterium tuberculosis (M. tb), resulting in approximately 1.3 million deaths in 2022 worldwide. Oral therapy with anti-TB drugs often fails to achieve therapeutic concentrations at the primary infection site (lungs). In this study, we developed a dry powder inhalable formulation (DPI) of clofazimine (CFZ) to provide localized drug delivery and minimize systemic adverse effects. Poly (lactic acid-co-glycolic acid) (PLGA) microparticles (MPs) containing CFZ were developed through a single emulsion solvent evaporation technique. Clofazimine microparticles (CFZ MPs) displayed entrapment efficiency and drug loading of 66.40 ± 2.22 %w/w and 33.06 ± 1.45 µg/mg, respectively. To facilitate pulmonary administration, MPs suspension was spray-dried to yield a dry powder formulation (CFZ SD MPs). Spray drying had no influence on particle size (~1 µm), zeta potential (−31.42 mV), and entrapment efficiency. Solid state analysis (PXRD and DSC) of CFZ SD MPs studies demonstrated encapsulation of the drug in the polymer. The drug release studies showed a sustained drug release. The optimized formulation exhibited excellent aerosolization properties, suggesting effective deposition in the deeper lung region. The in vitro antibacterial studies against H37Ra revealed improved (eight-fold) efficacy of spray-dried formulation in comparison to free drug. Hence, clofazimine dry powder formulation presents immense potential for the treatment of tuberculosis with localized pulmonary delivery and improved patient compliance. Full article
(This article belongs to the Special Issue Emerging Trends in Inhaled Drug Delivery)
Show Figures

Graphical abstract

16 pages, 4641 KiB  
Article
The Impact of Grain Growth on the Functional Properties in Room-Temperature Powder Aerosol Deposited Free-Standing (Ba,Ca)(Zr,Ti)O3 Thick Films
by Juliana G. Maier, Tim Fuggerer, Daisuke Urushihara, Alexander Martin, Neamul H. Khansur, Ken-ichi Kakimoto and Kyle G. Webber
Crystals 2024, 14(4), 296; https://doi.org/10.3390/cryst14040296 - 22 Mar 2024
Viewed by 1921
Abstract
This study investigates the development of freestanding thick films (FSFs) of lead-free (Ba,Ca)(Zr,Ti)O3 and the role of grain growth on the electromechanical response. During deposition, room temperature powder aerosol deposition rapidly produces thick films with a nano-grain structure that limits the electromechanical [...] Read more.
This study investigates the development of freestanding thick films (FSFs) of lead-free (Ba,Ca)(Zr,Ti)O3 and the role of grain growth on the electromechanical response. During deposition, room temperature powder aerosol deposition rapidly produces thick films with a nano-grain structure that limits the electromechanical properties. In this study, the films are removed from the substrate using a sacrificial buffering layer to avoid thermal treatment and allow for an initial as-processed state. Following this, FSFs were thermally treated at various annealing temperatures from 800 °C to 1400 °C to induce grain growth, which was characterized with scanning and transmission electron microscopy. X-ray diffraction revealed an increase in the crystallite size consistent with an increase in grain size and a decrease in internal residual stress. The temperature-dependent dielectric behavior and the large-field ferroelectric response were also characterized, revealing significant differences of the FSFs from the bulk properties. Full article
(This article belongs to the Special Issue Advanced Ferroelectric, Piezoelectric and Dielectric Ceramics)
Show Figures

Graphical abstract

15 pages, 8738 KiB  
Article
Mixed-Potential Ammonia Sensor Based on a Dense Yttria-Stabilized Zirconia Film Manufactured at Room Temperature by Powder Aerosol Deposition
by Nils Donker, Daniela Schönauer-Kamin and Ralf Moos
Sensors 2024, 24(3), 811; https://doi.org/10.3390/s24030811 - 26 Jan 2024
Cited by 4 | Viewed by 1536
Abstract
Powder aerosol deposition (often abbreviated as PAD, PADM, or ADM) is a coating method used to obtain dense ceramic films at room temperature. The suitability of this method to obtain ammonia mixed-potential sensors based on an yttria-stabilized zirconia (YSZ) electrolyte that is manufactured [...] Read more.
Powder aerosol deposition (often abbreviated as PAD, PADM, or ADM) is a coating method used to obtain dense ceramic films at room temperature. The suitability of this method to obtain ammonia mixed-potential sensors based on an yttria-stabilized zirconia (YSZ) electrolyte that is manufactured using PAD and a V2O5–WO3–TiO2 (VWT)-covered electrode is investigated in this study. The sensor characteristics are compared with data from sensors with screen-printed YSZ solid electrolytes. The PAD sensors outperform those in terms of sensitivity with 117 mV/decade NH3 compared to 88 mV/decade. A variation in the sensor temperature shows that the NH3 sensitivity strongly depends on the sensor temperature and decreases with higher sensor temperature. Above 560 °C, the characteristic curve shifts from exponential to linear dependency. Variations in the water and the oxygen content in the base gas (usually 10% oxygen, 2% water vapor in nitrogen) reveal a strong dependence of the characteristic curve on the oxygen content. Water vapor concentration variations barely affect the sensor signal. Full article
(This article belongs to the Special Issue Chemical Sensors—Recent Advances and Future Challenges 2023–2024)
Show Figures

Figure 1

21 pages, 2576 KiB  
Review
Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System
by Tomasz R. Sosnowski
Pharmaceutics 2024, 16(1), 97; https://doi.org/10.3390/pharmaceutics16010097 - 10 Jan 2024
Cited by 6 | Viewed by 3656
Abstract
Pharmaceutical aerosols play a key role in the treatment of lung disorders, but also systemic diseases, due to their ability to target specific areas of the respiratory system (RS). This article focuses on identifying and clarifying the influence of various factors involved in [...] Read more.
Pharmaceutical aerosols play a key role in the treatment of lung disorders, but also systemic diseases, due to their ability to target specific areas of the respiratory system (RS). This article focuses on identifying and clarifying the influence of various factors involved in the generation of aerosol micro- and nanoparticles on their regional distribution and deposition in the RS. Attention is given to the importance of process parameters during the aerosolization of liquids or powders and the role of aerosol flow dynamics in the RS. The interaction of deposited particles with the fluid environment of the lung is also pointed out as an important step in the mass transfer of the drug to the RS surface. The analysis presented highlights the technical aspects of preparing the precursors to ensure that the properties of the aerosol are suitable for a given therapeutic target. Through an analysis of existing technical limitations, selected strategies aimed at enhancing the effectiveness of targeted aerosol delivery to the RS have been identified and presented. These strategies also include the use of smart inhaling devices and systems with built-in AI algorithms. Full article
(This article belongs to the Special Issue Drug Delivery Systems for Respiratory Diseases)
Show Figures

Figure 1

22 pages, 11453 KiB  
Article
Improving Inhalation Performance with Particle Agglomeration via Combining Mechanical Dry Coating and Ultrasonic Vibration
by Qingzhen Zhang, Zheng Wang, Kaiqi Shi, Hang Zhou, Xiaoyang Wei and Philip Hall
Pharmaceutics 2024, 16(1), 68; https://doi.org/10.3390/pharmaceutics16010068 - 31 Dec 2023
Cited by 6 | Viewed by 2465
Abstract
Agglomerate formulations for dry powder inhalation (DPI) formed with fine particles are versatile means for the highly efficient delivery of budesonide. However, uncontrolled agglomeration induces high deposition in the upper airway, causing local side effects due to high mechanical strength, worse deagglomeration, and [...] Read more.
Agglomerate formulations for dry powder inhalation (DPI) formed with fine particles are versatile means for the highly efficient delivery of budesonide. However, uncontrolled agglomeration induces high deposition in the upper airway, causing local side effects due to high mechanical strength, worse deagglomeration, and poor fine-particle delivery. In the present study, fine lactose was mechanically dry-coated prior to particle agglomeration, and the agglomerates were then spheroidized via ultrasonic vibration to improve their aerosol performance. The results showed that the agglomerate produced with the surface-enriched hydrophobic magnesium stearate and ultrasonic vibration demonstrated improved aerosolization properties, benefiting from their lower mechanical strength, less interactive cohesive force, and improved fine powder dispersion behavior. After dispersion utilizing a Turbuhaler® with a pharmaceutical cascade impactor test, a fine particle fraction (FPF) of 71.1 ± 1.3% and an artificial throat deposition of 19.3 ± 0.4% were achieved, suggesting the potential to improve the therapeutic outcomes of budesonide with less localized infections of the mouth and pharynx. Full article
Show Figures

Graphical abstract

17 pages, 3467 KiB  
Article
Evaluation of a Novel Dry Powder Surfactant Aerosol Delivery System for Use in Premature Infants Supported with Bubble CPAP
by Robert M. DiBlasi, Coral N. Crandall, Rebecca J. Engberg, Kunal Bijlani, Dolena Ledee, Masaki Kajimoto and Frans J. Walther
Pharmaceutics 2023, 15(10), 2368; https://doi.org/10.3390/pharmaceutics15102368 - 22 Sep 2023
Cited by 6 | Viewed by 2648
Abstract
Aerosolized lung surfactant therapy during nasal continuous positive airway pressure (CPAP) support avoids intubation but is highly complex, with reported poor nebulizer efficiency and low pulmonary deposition. The study objective was to evaluate particle size, operational compatibility, and drug delivery efficiency with various [...] Read more.
Aerosolized lung surfactant therapy during nasal continuous positive airway pressure (CPAP) support avoids intubation but is highly complex, with reported poor nebulizer efficiency and low pulmonary deposition. The study objective was to evaluate particle size, operational compatibility, and drug delivery efficiency with various nasal CPAP interfaces and gas humidity levels of a synthetic dry powder (DP) surfactant aerosol delivered by a low-flow aerosol chamber (LFAC) inhaler combined with bubble nasal CPAP (bCPAP). A particle impactor characterized DP surfactant aerosol particle size. Lung pressures and volumes were measured in a preterm infant nasal airway and lung model using LFAC flow injection into the bCPAP system with different nasal prongs. The LFAC was combined with bCPAP and a non-heated passover humidifier. DP surfactant mass deposition within the nasal airway and lung was quantified for different interfaces. Finally, surfactant aerosol therapy was investigated using select interfaces and bCPAP gas humidification by active heating. Surfactant aerosol particle size was 3.68 µm. Lung pressures and volumes were within an acceptable range for lung protection with LFAC actuation and bCPAP. Aerosol delivery of DP surfactant resulted in variable nasal airway (0–20%) and lung (0–40%) deposition. DP lung surfactant aerosols agglomerated in the prongs and nasal airways with significant reductions in lung delivery during active humidification of bCPAP gas. Our findings show high-efficiency delivery of small, synthetic DP surfactant particles without increasing the potential risk for lung injury during concurrent aerosol delivery and bCPAP with passive humidification. Specialized prongs adapted to minimize extrapulmonary aerosol losses and nasal deposition showed the greatest lung deposition. The use of heated, humidified bCPAP gases compromised drug delivery and safety. Safety and efficacy of DP aerosol delivery in preterm infants supported with bCPAP requires more research. Full article
(This article belongs to the Section Drug Delivery and Controlled Release)
Show Figures

Figure 1

13 pages, 1473 KiB  
Article
Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection
by Donna M. Konicek, Adam J. Plaunt, Sachin Gharse, Sasha J. Rose, Arielle Dorfman, Amruta Sabnis, Thomas Baker, Helena Gauani, Donald Chun, Zhili Li, Walter R. Perkins, David Cipolla and Vladimir S. Malinin
Pharmaceutics 2023, 15(9), 2250; https://doi.org/10.3390/pharmaceutics15092250 - 31 Aug 2023
Cited by 1 | Viewed by 2055
Abstract
The increased prevalence of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infection in patients living with cystic fibrosis (CF) is concerning due to a correlation with reduced life expectancy and lack of available treatment options. RV94 is a next generation lipoglycopeptide designed for pulmonary delivery [...] Read more.
The increased prevalence of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) infection in patients living with cystic fibrosis (CF) is concerning due to a correlation with reduced life expectancy and lack of available treatment options. RV94 is a next generation lipoglycopeptide designed for pulmonary delivery that preclinically demonstrated high potency against MRSA in planktonic and protected colonies and improved pulmonary clearance relative to same class molecules. Here, RV94 was formulated into a dry powder for inhalation (DPI) to investigate the localized treatment of pulmonary MRSA presented in a potentially more convenient dosage form. RV94 DPI was generated using a spray-drying process with 12.5 wt% trileucine and demonstrated aerosol characteristics (2.0 μm MMAD and 73% FPF) predictive of efficient pulmonary deposition. In vivo PK from a single dose of RV94 DPI delivered by inhalation to rats yielded lung levels (127 μg/g) much greater than the MRSA minimum inhibitory concentration (0.063 μg/mL), low systemic levels (0.1 μg/mL), and a lung t1/2 equal to 3.5 days. In a rat acute pulmonary MRSA model, a single dose of RV94 DPI delivered by inhalation either up to seven days prior to or 24 h after infection resulted in a statistically significant reduction in lung MRSA titer. Full article
(This article belongs to the Special Issue Medical Aerosol Drug Delivery, 2nd Edition)
Show Figures

Figure 1

Back to TopTop